- New data on COVID-19 Influenza combination vaccine and
seasonal influenza vaccine to be presented at World Vaccine
Congress
- Several abstracts and presentations slated to highlight
updates on NVX-CoV2373, Novavax' COVID-19 vaccine
GAITHERSBURG, Md., April 18,
2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
biotechnology company dedicated to developing and commercializing
next-generation vaccines for serious infectious diseases, will
provide a first look at data from its COVID-19 influenza
combination vaccine and seasonal influenza vaccine trials, at the
World Vaccine Congress (WVC) in Washington, DC, April
18 - 21, 2022. In addition, the latest data on its
protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be
presented at both WVC and the 32nd European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID) in in Lisbon, Portugal, April
23 - 26, 2022. Data from eight abstracts and presentations,
including four oral presentations, will be presented across the two
congresses.
Gregory M. Glenn, M.D.,
President, Research and Development, Novavax, said: "Our presence
at these two leading industry conferences shows our ongoing
commitment to addressing COVID-19, and the advances we have made
towards a next-generation influenza vaccine. We look forward to
sharing these updates that further demonstrate the potential for
our platform."
Key Novavax presentations during WVC:
Glenn, G
|
How long will our
immunity
against COVID-19 last for
and will our vaccines
continue to work against
VoCs?
|
Panel
April 19,
2022
8:45 – 9:45
ET
|
Kim, D
|
Monitoring COVID-19
Vaccine
Safety under Emergency Use
Authorization: Challenges and
Lessons?
|
Panel
April 20,
2022
12:10 – 1:10
ET
|
Glenn, G
|
Clinical Update on
Novavax's
Recombinant Nanoparticle Protein
Subunit COVID-19 Vaccine as a
Booster
|
Oral
Session COVID &
Beyond – M4
April 20,
2022
12:40 – 12:00
ET
|
Shinde, V
|
Update on Novavax'
NanoFlu*
vaccine and COVID-19-Influenza
Combination Vaccine development
|
Oral
Session Influenza and
Respiratory – M4
April 20,
2022
12:40 – 1:10
ET
|
*NanoFlu identifies a recombinant hemagglutinin (HA)
protein nanoparticle influenza vaccine candidate produced by
Novavax. This investigational candidate was evaluated during a
controlled phase 3 trial conducted during the 2019-2020 influenza
season.
Key Novavax presentations during ECCMID:
Toback, S
|
Ongoing safety and
efficacy
of the NVX-CoV2373 COVID-19
vaccine in the United Kingdom
|
Abstract
#04525
Oral
Session Late breaking
updates on COVID vaccination
April 25,
2022
16:15 – 17:15
CET
|
Shinde, V
|
Long-term durability
of
antigen-specific polyfunctional
CD4+ T cell responses against
vaccine-homologous and
antigenically drifted viruses:
results of a phase III trial
of a recombinant quadrivalent
hemagglutinin saponin-adjuvanted
nanoparticle influenza
|
Abstract
#1197
Oral
Session Viral
respiratory infections: Influenza and RSV
April 26,
2022
11:00 – 12:00
CET
|
Áñez, G
|
Safety, efficacy and
effectiveness
of a SARS-CoV-2 adjuvanted
recombinant spike protein
vaccine (NVX-CoV2373)
in a phase III trial in
adolescents (PREVENT-19)
|
Abstract
#04455
Poster
Session 12g. Vaccine
development, trials, efficacy, policy
April 25,
2022
12:00 – 13:00
CET
|
Áñez, G
|
Molecular epidemiology
of SARS-CoV-2
strains identified during a phase III,
efficacy and safety trial of
NVX-CoV2373 vaccine
(PREVENT-19) in the
United States and Mexico
|
Abstract
#00284
Poster
Session 12l. Virus
evolution, variants, and impact
April 25,
2022
12:00 – 13:00
CET
|
Beyhaghi, H
|
Reported pregnancies
and
associated outcomes across
the NVX-CoV2373 COVID-19
vaccine clinical development
programme
|
Abstract
#01705
Poster
Session 12g. Vaccine
development, trials, efficacy, policy
April 25,
2022
12:00 – 13:00
CET
|
Marchese, A
|
COVID-19 vaccine
receptivity
and preferences among
"vaccine hesitants"
|
Abstract
#04362
Poster
Session 12g. Vaccine
development, trials, efficacy, policy
April 25,
2022
12:00 – 13:00
CET
|
For more information or to register, visit the World
Vaccine Congress Washington 2022 and the 32nd European Congress of
Clinical Microbiology & Infectious Diseases websites.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a
biotechnology company that promotes improved health globally
through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The
company's proprietary recombinant technology platform harnesses the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. NVX-CoV2373, the company's COVID-19 vaccine, has
received conditional authorization from multiple regulatory
authorities globally, including the European Commission and the
World Health Organization. The vaccine is also under review by
multiple regulatory agencies worldwide. In addition to its COVID-19
vaccine, Novavax is also currently evaluating a COVID-seasonal
influenza combination vaccine in a Phase 1/2 clinical trial, which
combines NVX-CoV2373 and its quadrivalent influenza investigational
vaccine candidate, previously referred to as NanoFlu. These vaccine
candidates incorporate Novavax' proprietary saponin-based Matrix-M™
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on LinkedIn,.
Contacts:
Investors
Erika Schultz |
240-268-2022
ir@novavax.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey |
202-709-7521
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-grows-presence-at-world-vaccine-congress-and-32nd-european-congress-of-clinical-microbiology--infectious-diseases-301527065.html
SOURCE Novavax, Inc.